Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders (2017 - 2026)

Takeda Pharmaceutical's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at $710.2 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 17.29% year-over-year to $710.2 million; the TTM figure through Jun 2026 stood at $574.3 million (down 76.16% YoY), while the FY2026 annual figure was -$1.0 billion, down 242.88% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at $710.2 million, down from $792.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.0 billion in Q3 2023, with the low at -$2.4 billion in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is $751.1 million (2026), against an average of $548.8 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 912.2% in 2023, then slumped 422.64% in 2024.
• Takeda Pharmaceutical's Net Income towards Common Stockholders stood at $843.2 million in 2022, then sank by 75.05% to $210.4 million in 2023, then plunged by 422.64% to -$678.8 million in 2024, then slumped by 252.74% to -$2.4 billion in 2025, then soared by 129.66% to $710.2 million in 2026.
• Business Quant data shows TAK's Net Income towards Common Stockholders at $710.2 million in Q2 2026, $792.0 million in Q1 2026, and -$2.4 billion in Q4 2025.